CARDINAL HEALTH INC
For the period ended Nov 5, 2025. Filed Sep 16, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Nov 5, 2025 · Filed Sep 16, 2025
Contents
Driving Future Value Creation Through Strategic Execution
Fiscal 2025 was a transformative year for Cardinal Health. Through internal and external investments, disciplined execution, and a relentless focus on simplification, management advanced the company’s long-term strategic priorities: building upon the growth and resiliency of the Pharma segment through continued expansion in Specialty; accelerating momentum across the company’s high-potential growth businesses; and executing GMPD Improvement Plan initiatives. The Board actively oversaw these efforts through regular strategy sessions, enterprise risk reviews, and performance updates, providing guidance and input as management executed initiatives that streamlined operations, enhanced customer experience, and reinforced the company’s commitment to long-term value creation for shareholders.
| CARDINAL HEALTH 2025 Proxy Statement | 5 |
|---|
| Building Upon the Growth and Resiliency of Pharmaceutical and Specialty Solutions | In fiscal 2025, the Board provided strategic oversight of several acquisitions that expanded Cardinal Health’s presence in Specialty, specifically in gastroenterology, urology, and oncology. The acquisitions of Integrated Oncology Network (“ION”), GI Alliance, and Urology America laid the foundation for the launch of The Specialty Alliance multi-specialty management services organization (“MSO”) platform and strengthened the company’s Navista oncology practice alliance. These investments meaningfully enhanced the company’s focus on multiple specialties and our ability to provide a broad suite of services supporting specialty physicians. The Board evaluated each initiative for strategic and cultural fit and financial return as well as for its implications on long-term term shareholder value creation and enterprise resilience. |
| Accelerating Growth in the Company’s Other Businesses | Cardinal Health’s growth businesses, Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight® Logistics — collectively reported in “Other” — delivered strong fiscal 2025 growth. Accelerating this momentum was the acquisition of Advanced Diabetes Supply Group, one of the country’s leading diabetic medical supplies providers, which expanded the company’s reach in diabetes care. Strategic investments in automation and digital platforms further enhanced operational efficiency and customer experience. These businesses, recognized as leaders within their respective areas of healthcare, were a focal point of the Board’s capital deployment decisions and strategic planning given their alignment with key secular trends, positive long-term outlook, and higher-margin opportunities. |
| Executing the Global Medical Products and Distribution Improvement Plan | The GMPD segment continued its multi-year transformation, growing segment profit by 47% in fiscal 2025 after returning the business to profitability in fiscal 2024. The Board oversaw and monitored execution of GMPD Improvement Plan initiatives, including cost optimization and Cardinal Health™ Brand growth strategies. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.